ELF · e.l.f. Beauty, Inc. · Stock research

Current Thesis

The July setup — desks marking targets up while the stock slid to $72.25 on 2026-07-14 — resolved on 2026-08-05: adjusted EPS $1.75 against $0.72 consensus, net sales $479.373M against $429.192M, FY2027 guidance lifted to $3.50–3.55 adjusted EPS (from $3.27–3.32) and $1.938–1.968B sales (from $1.835–1.865B), with the full-year sales-growth outlook taken to 18–20% from 12–14%. Shares closed $91.44 on 2026-08-14 and $101.94 on 2026-08-21, a three-month price change of +92.7% and 30.5% under the $146.67 52-week high.

What has changed since the last update is the relationship between price and the sell-side, not the fundamentals. On 2026-08-22 the consensus across 18 analysts was Moderate Buy with an average one-year target of $91.31 — below the 08-21 close. JPMorgan cut its target from $111 to $106 on 2026-08-19 while keeping Overweight, the first downward revision of this cycle, on the same day Canaccord Genuity raised from $97 to $110. The narrative leg being bought is unchanged: a two-brand growth stack (rhode at $160M of the $479.4M June quarter, versus $113M in Q4 FY2026; e.l.f. Hair in all Target doors since 2026-07-05) re-rating a decelerating value-cosmetics core. Price has simply run past where most of the desks put it.

The narrative is maturing. Dating it: the revision cluster peaked on 2026-08-06 with five target raises in a single session; between 08-11 and 08-21 the tape produced two analyst actions, one of them a cut. RSI(14) read 76.6 on Benzinga's 2026-08-07 risk-off screen, cooled to 61.8 by 08-14, and was back at 73.5 on 08-21 — price making a new leg high on moderating headline flow. Reported institutional and hedge-fund ownership stood at 92.44% on 2026-08-22.

Bullish and bearish views on e.l.f. Beauty, Inc.

The model's bull view on e.l.f. Beauty, Inc. (ELF), in brief: The 2026-08-05 revision was a full-year forward raise, roughly $100M added at both ends of the FY2027 sales range and the growth outlook moved from 12–14% to 18–20% — a re-based number, not a single-quarter catch-up. The bear view: Price is through the mean target. The 08-21 close of $101.94 against a $91.31 average across 18 analysts on 08-22, with the distribution still 1 sell / 5 hold / 10 buy / 2 strong buy. Piper Sandler's $65 Neutral, set 2026-08-06, has not been revised. JPMorgan cut into strength.… Both cases follow in full.

Bull Case

• The 2026-08-05 revision was a full-year forward raise, roughly $100M added at both ends of the FY2027 sales range and the growth outlook moved from 12–14% to 18–20% — a re-based number, not a single-quarter catch-up.
• rhode's channel expansion is dated and unmodeled. Per the company's 2026-04-30 release, rhode enters Sephora Europe from September 2026 as an "Only at Sephora" exclusive across 19 markets including France, Germany, Italy, Spain, Poland and Turkey, following North America and UK launches in 2025 that the company described as the largest brand launches in that retailer's NA and UK histories.
• Top of the target range keeps moving up. Canaccord $97→$110 on 2026-08-19, TD Cowen $85→$110 on 08-10, Bernstein $113→$121 on 08-06 with the only rating change of the cycle (to Outperform, 08-05). Zacks Research moved to strong buy on 2026-08-12.
• rhode's demand signal is quantified, not anecdotal. Management told the 08-05 call the June summer range (Pocket Bronze, Highlight Milk) did $27M of DTC sales in one day and drew 90,000 new consumers, 70% of them repeat buyers.
• e.l.f. Hair is recruiting. On the same call, management said more than half of hair-care purchasers were new to e.l.f. Beauty, at $6–9 price points inside Target.

Bear Case

• Price is through the mean target. The 08-21 close of $101.94 against a $91.31 average across 18 analysts on 08-22, with the distribution still 1 sell / 5 hold / 10 buy / 2 strong buy. Piper Sandler's $65 Neutral, set 2026-08-06, has not been revised.
• JPMorgan cut into strength. $111 to $106 on 2026-08-19, Overweight maintained — the first target reduction since the July re-rating began, arriving as the stock made new highs for the move.
• director Lauren Cooks Levitan sold 1,034 at $93.15 on 08-18; CMO Kory Marchisotto sold 12,173 at $88.0157 on 08-04 under the same-dated plan. Director share additions on 08-20 (Farrell 1,421, Keith 1,985, Daniele 1,421) were RSU grants, not open-market purchases.
• Concentration is the growth rate. rhode was $160M of $479.4M in Q1 FY2027; a slower European ramp or a softer autumn drop cadence shows up directly in the consolidated line.
• Cost exposure is unresolved. Roughly three-quarters of production was China-sourced as disclosed at the FY2026 Q4 report, so the FY2027 EPS bridge carries a tariff assumption that headlines can move without any company action.
• Momentum is stretched again. RSI(14) 73.5 on 08-21, back near the 76.6 that put the name on a published risk-off screen two weeks earlier alongside HNST (89.7) and JJSF (81.9).

Setup & Price Structure

Dated closes define the structure: $76.42 on 2026-07-03, $72.25 on 2026-07-14, $91.44 on 2026-08-14, $101.94 on 2026-08-21. The pre-print zone is $72–77; the post-print zone is $88–102. The only public dated price reference immediately before the 08-05 report is the 2026-08-04 Form 4 average sale price of $88.02, which puts the whole beat-and-raise reaction between roughly $88 and the 08-21 close.

That makes $88 the structural floor of the reaction: a weekly close beneath it returns the stock to where it traded before the guidance was raised, and beneath the $91.31 consensus average. The gap between $77 and $88 has no dated closes to reference and would be traversed on air. At 30.5% below the $146.67 52-week high with a +92.7% three-month price change, the name is simultaneously deep in a multi-year drawdown and extended over its own three-month base — those are not in conflict, but they attract different buyers, and the second cohort has no dated event to hold for.

Catalyst Calendar (next 30 days)

• ~2026-11-04 (est.) — Q2 FY2027 earnings, outside the window. This is the next quantified checkpoint on the $160M rhode run-rate and the $1.938–1.968B FY2027 sales guide.

Elapsed catalysts

• ~2026-09 (est., no day published) — rhode launches into Sephora Europe, 19 countries, online plus most physical doors, as an "Only at Sephora" exclusive (company release 2026-04-30). No specific launch date has been published; the investor-relations events page listed no upcoming events as of 2026-08-23. (passed 3d ago)
• No confirmed company-dated event falls inside the next 30 days. The window from 2026-08-23 to late September contains the rollout and nothing scheduled. (passed 3d ago)

What Would Change Our Mind

The structure that would break first is the post-print range itself. Shares have held between roughly $88 and $102 since 2026-08-05; a weekly close below $88 gives back the entire beat-and-raise reaction and returns price to the pre-guidance zone, with the $91.31 consensus average then sitting overhead rather than beneath.

Three non-price observables would do the same work more slowly. First, September passing without any quantified sell-out, ranking or door-count datapoint from the Sephora Europe rollout — the launch is the only thing standing between now and the November print, and silence through it leaves the $91–121 target spread resting on a single quarter. Second, rhode net sales printing below $160M sequentially at Q2 FY2027, or management declining to size the European contribution on that call. Third, further downward target revisions following JPMorgan's 08-19 cut while the Piper Sandler $65 mark stays unrevised — that pattern would mark the July–August mark-up as complete rather than continuing.

The reverse case: a quantified European launch datapoint in September, plus a second consecutive FY2027 guidance raise in November, would extend the leg and make the current consensus average the stale number rather than the price.

Correlation Notes

• Retail gatekeepers. e.l.f. Hair is Target-exclusive, so Target's next quarterly report — its US comparable sales and any beauty shelf-space commentary — is a direct read-through. Rhode's growth now runs through Sephora (LVMH), concentrating channel risk in two retailers.
• Tariff tape. With ~75% China sourcing disclosed at the FY2026 Q4 report, US-China consumer-goods tariff headlines move the FY2027 EPS bridge independently of demand.
• Momentum cohort. The 2026-08-07 risk-off screen grouped ELF with HNST and JJSF on RSI; the name trades with small- and mid-cap momentum unwinds more than with staples-defensive flows, despite the sector label.
• Celebrity-brand comparison set. rhode's trajectory is the reference case other founder-brand acquisitions are marked against; a disappointing European launch would be read across that cohort, and vice versa.